Mark Dibuono, MD
Psychiatry · Staten Island, NYNPI 1538143680
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,011 of the $17,837 with a category attached, or 61.7%. 30 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 38.2% of the total. Reporting peaked in 2019 at $5,003 and has fallen 97.0% since, to $148 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 593 payments — averaging $30.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$7K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$947
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$827
- Alkermes, Inc.$781
- plus $4K from 24 others
Across 943 payments — averaging $12,593 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$4.9M
- Genentech, Inc.$1.6M
- Eli Lilly$1.3M
- Teva Pharmaceuticals USA, Inc.$761K
- F. Hoffmann-la Roche AG$381K
- Biogen$341K
- plus $2.7M from 31 others
What the payments were for
- Speaking & faculty fees$6,44036%
- Food & beverage$11,01162%
- Education$3862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 39 | $6,813 |
| AbbVie(2 entities) | 136 | $2,498 |
| Teva Pharmaceuticals USA, Inc. | 72 | $1,632 |
| Otsuka America Pharmaceutical, Inc. | 51 | $947 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $827 |
| Alkermes, Inc. | 40 | $781 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $750 |
| Lundbeck LLC | 39 | $701 |
| Johnson & Johnson | 17 | $372 |
| Neurocrine Biosciences, Inc. | 11 | $346 |
| Indivior Inc. | 12 | $273 |
| Jazz Pharmaceuticals Inc. | 12 | $254 |
| Bausch Health US, LLC | 12 | $236 |
| Eisai Inc. | 9 | $189 |
| Axsome Therapeutics, Inc. | 6 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $133 |
| Almatica Pharma LLC | 6 | $122 |
| Ironshore Pharmaceuticals Inc. | 5 | $120 |
| Acadia Pharmaceuticals Inc | 5 | $102 |
| Shire North American Group Inc | 5 | $96 |
| Adlon Therapeutics L.p. | 6 | $89 |
| Supernus Pharmaceuticals, Inc. | 5 | $87 |
| Merck | 4 | $62 |
| Validus Pharmaceuticals LLC | 4 | $58 |
| Noven Therapeutics, LLC | 3 | $55 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Biogen | 1 | $22 |
| Neuronetics, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,837 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 17 | $125,791 |
| RexultiBrexpiprazole | 58 | $98,013 |
| AplenzinBupropion Hbr | 12 | $71,654 |
| PerserisRisperidone | 21 | $68,993 |
| Lurasidone Hcl | 79 | $39,806 |
| VraylarCariprazine Hcl | 18 | $27,544 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,394 |
| SpravatoEsketamine Hcl | 15 | $23,445 |
| TrintellixVortioxetine Hydrobromide | 29 | $21,078 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $11,061 |
| Aripiprazole | 145 | $4,233 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 99 | $4,230 |
| Rivastigmine | 21 | $3,454 |
| Quetiapine Fumarate | 170 | $3,320 |
| Mirtazapine | 120 | $2,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,632 | $125,79117 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $947 | $98,01358 claims |
| Bausch Health US, LLCAplenzin | $236 | $71,65412 claims |
| Indivior Inc.Perseris | $273 | $68,99321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $750 | $32,13960 claims |
| AbbVieVraylar | $2,498 | $27,54418 claims |
| Alkermes, Inc.Lybalvi | $781 | $24,39415 claims |
| Johnson & JohnsonSpravato | $372 | $23,44515 claims |
| Almatica Pharma LLCSertraline Hcl | $122 | $805122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Staten Island
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.